Semaglutide is a GLP-1 receptor agonist used, under the brand names Ozempic and Wegovy, for type 2 diabetes and chronic weight management. This page reproduces the published prescribing information and the mg→units math for reference only; it is not a dosing recommendation.
Pure arithmetic for the example reconstitution below: how many units on a U-100 insulin syringe a given dose corresponds to. units = doseMg ÷ (vialMg ÷ bacMl) × 100. These are unit conversions, not a dosing recommendation.
| Dose | Units (U-100) | Volume |
|---|---|---|
| 0.25 mg | 10.0 U | 0.100 mL |
| 0.5 mg | 20.0 U | 0.200 mL |
| 1 mg | 40.0 U | 0.400 mL |
| 1.7 mg | 68.0 U | 0.680 mL |
| 2.4 mg | 96.0 U | 0.960 mL |
For weight management (Wegovy), the FDA prescribing information describes a fixed 16-week escalation before the maintenance dose, raising the dose every 4 weeks to improve gastrointestinal tolerability:
0.25 mg weekly (weeks 1–4) → 0.5 mg (weeks 5–8) → 1.0 mg (weeks 9–12) → 1.7 mg (weeks 13–16) → 2.4 mg as the maintenance dose from week 17. The label states the 0.25 mg starting dose is for initiation and is not intended for glycaemic or weight effect.
As of: June 21, 2026
Need the math for your own setup? Use the neutral, drug-agnostic tools — they come with no pre-loaded "recommended" dose.